{
  "id": 20788910,
  "title": "Evaxion (EVAX) Q3 2026 Earnings Call Transcript",
  "url": "https://urgent.news/2026/11/19/evaxion-evax-q3-2026-earnings-call-transcript",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T18:54:40.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/earnings/call-transcripts/2026/11/19/evaxion-evax-q3-2026-earnings-call-transcript/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Evaxion (EVAX) held its Q3 2026 earnings call, focusing on a strategic refocus on its AI-Immunology platform for oncology programs. The company reported an extended cash runway until the end of 2027, achieved through disciplined resource allocation and at-the-market equity sales. Clinical validation for Evaxion's platform was showcased through three-year phase II data for the EVX-01 vaccine, which demonstrated high target precision and durable immune responses in metastatic melanoma. Moving forward, Evaxion plans to concentrate its resources in three key areas: furthering the development of off-the-shelf cancer vaccines EVX-04 and EVX-05, expanding the potential of EVX-01 beyond advanced melanoma, and identifying new antigens and indications through deeper analysis of the dark genome with AI-Immunology. The company's pipeline will focus solely on oncology assets, while preclinical assets in infectious disease and autoimmune disease will be pursued through partnerships.",
  "summary": "Runway stretches to 2027 as oncology vaccine focus sharpens.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}